171 related articles for article (PubMed ID: 31407671)
1. Safety and Efficacy of Bis-Glyceryl Ascorbate (Amitose DGA) to Prevent Hand-Foot Skin Reaction in Patients With Renal Cell Carcinoma Receiving Sunitinib Therapy: Protocol for a Phase I/II, Uncontrolled, Single-Arm, Open-Label Trial.
Yamamoto K; Ioroi T; Harada K; Nishiyama S; Nishigori C; Yano I
JMIR Res Protoc; 2019 Aug; 8(8):e14636. PubMed ID: 31407671
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II Study (DGA Study).
Yamamoto K; Nishiyama S; Kunisada M; Iida M; Ito T; Ioroi T; Makimoto H; Omura T; Harada K; Fujisawa M; Nishigori C; Yano I
Oncologist; 2022 May; 27(5):e384-e392. PubMed ID: 35285503
[TBL] [Abstract][Full Text] [Related]
3. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
Chu D; Lacouture ME; Weiner E; Wu S
Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662
[TBL] [Abstract][Full Text] [Related]
4. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.
Manchen E; Robert C; Porta C
J Support Oncol; 2011; 9(1):13-23. PubMed ID: 21465734
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Topical Urea for Secondary Prophylaxis of Hand Foot Skin Reaction in Renal Cell Cancer Patients on Sunitinib Therapy.
Naeem SS; Gupta P; Sahoo RK; Kumar VL; Velpandian T; Singh A; Batra A; Pramanik R; Rastogi S; Srivastava S
Clin Genitourin Cancer; 2024 Jun; 22(3):102073. PubMed ID: 38626661
[TBL] [Abstract][Full Text] [Related]
6. Comparing Telemedicine and Face-to-Face Consultation Based on the Standard Smoking Cessation Program for Nicotine Dependence: Protocol for a Randomized Controlled Trial.
Tanigawa T; Nomura A; Kuroda M; Muto T; Hida E; Satake K
JMIR Res Protoc; 2019 Jul; 8(7):e12701. PubMed ID: 31290402
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial.
Nishizawa A; Shinozaki E; Wakatsuki T; Satoh T; Yamazaki N; Oyamada S; Ariyoshi K; Kihara K; Tsuboi M; Yamaguchi K
BMC Cancer; 2023 May; 23(1):401. PubMed ID: 37142953
[TBL] [Abstract][Full Text] [Related]
9. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
Shinohara N; Nonomura N; Eto M; Kimura G; Minami H; Tokunaga S; Naito S
Ann Oncol; 2014 Feb; 25(2):472-6. PubMed ID: 24351402
[TBL] [Abstract][Full Text] [Related]
10. A Novel Smoking Cessation Smartphone App Integrated With a Mobile Carbon Monoxide Checker for Smoking Cessation Treatment: Protocol for a Randomized Controlled Trial.
Nomura A; Tateno H; Masaki K; Muto T; Suzuki S; Satake K; Hida E; Fukunaga K
JMIR Res Protoc; 2019 Feb; 8(2):e12252. PubMed ID: 30741641
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the Self-management Support System DialBetesPlus for Diabetic Kidney Disease: Protocol for a Randomized Controlled Trial.
Kawai Y; Sankoda A; Waki K; Miyake K; Hayashi A; Mieno M; Wakui H; Tsurutani Y; Saito J; Hirawa N; Yamakawa T; Komiya S; Isogawa A; Satoh S; Minami T; Osada U; Iwamoto T; Takano T; Terauchi Y; Tamura K; Yamauchi T; Kadowaki T; Nangaku M; Kashihara N; Ohe K
JMIR Res Protoc; 2021 Aug; 10(8):e31061. PubMed ID: 34402802
[TBL] [Abstract][Full Text] [Related]
12. Fas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction.
Yeh CN; Chung WH; Su SC; Chen YY; Cheng CT; Lin YL; Chang WC; Chung-Yee Hui R; Chiang KC; Chen TW; Jan YY; Chen CW; Chen TJ; Yang CH; Hung SI
J Invest Dermatol; 2014 Nov; 134(11):2768-2775. PubMed ID: 24802849
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
McLellan B; Ciardiello F; Lacouture ME; Segaert S; Van Cutsem E
Ann Oncol; 2015 Oct; 26(10):2017-26. PubMed ID: 26034039
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Remote Cardiac Rehabilitation in the Recovery Phase of Cardiovascular Diseases: Protocol for a Multicenter, Nonrandomized, Single-Arm, Interventional Trial.
Itoh H; Amiya E; Narita K; Shimbo M; Taya M; Komuro I; Hasegawa T; Makita S; Kimura Y
JMIR Res Protoc; 2021 Oct; 10(10):e30725. PubMed ID: 34407925
[TBL] [Abstract][Full Text] [Related]
15. [Association between hand-foot skin reaction and effectiveness of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma].
Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Yihebali C; Zhou AP; Wang JW; Sun Y
Zhonghua Yi Xue Za Zhi; 2016 Sep; 96(34):2717-2721. PubMed ID: 27667104
[No Abstract] [Full Text] [Related]
16. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Pandy JGP; Franco PIG; Li RK
Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
[TBL] [Abstract][Full Text] [Related]
18. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition.
Hasan Alshammari A; Masuo Y; Fujita KI; Shimada K; Iida N; Wakayama T; Kato Y
Biochem Pharmacol; 2022 Mar; 197():114914. PubMed ID: 35041812
[TBL] [Abstract][Full Text] [Related]
19. Internet-Based Individualized Cognitive Behavioral Therapy for Shift Work Sleep Disorder Empowered by Well-Being Prediction: Protocol for a Pilot Study.
Ito-Masui A; Kawamoto E; Sakamoto R; Yu H; Sano A; Motomura E; Tanii H; Sakano S; Esumi R; Imai H; Shimaoka M
JMIR Res Protoc; 2021 Mar; 10(3):e24799. PubMed ID: 33626497
[TBL] [Abstract][Full Text] [Related]
20. Clinical study for external Chinese herbal medicine LC09 treating hand-foot skin reaction associated with the antitumor targeted drugs: Protocol for a prospective, randomized, controlled, double-blind, and monocentric clinical trial.
Wang G; Jia L; Pei Y; Yu R; Gao Y; Deng C; Lou Y
Medicine (Baltimore); 2020 Jan; 99(4):e18849. PubMed ID: 31977883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
